Key result
Maintaining intermediate or ideal cardiovascular health was associated with a 53% lower risk of all-cause mortality (HR 0.47) compared to poor cardiovascular health and significantly attenuated the detrimental impacts of cardiometabolic comorbidities.
Why the study?
Whether optimal cardiovascular health provides a protective role among individuals with preexisting cardiometabolic comorbidities and its extent of impact on longevity remained unknown.
Does intermediate or ideal cardiovascular health reduce all-cause mortality in individuals with cardiometabolic comorbidities?
Cohort (n=8,635)
Yes
Does intermediate or ideal cardiovascular health reduce all-cause mortality in individuals with cardiometabolic comorbidities?
Maintaining intermediate or ideal cardiovascular health significantly attenuates the mortality risk associated with cardiometabolic comorbidities.
Answers are grounded in this paper and cite their sources.
Optimal CVH may attenuate mortality risk with cardiometabolic comorbidities; leaves open causal benefits of LE8 improvement.
INTRODUCTION: Whether the protective role of optimal cardiovascular health (CVH) exists among individuals with preexisting cardiometabolic comorbidities and to what extent these impacts on longevity are unknown. This study aims to evaluate the protective effect on mortality in individuals with and without cardiometabolic comorbidities. MATERIALS AND METHODS: This cohort study utilized data from the China Health and Nutrition Survey. CVH was evaluated using the Life's Essential 8 (LE8) metric. Five cardiometabolic comorbidities, namely hypertension, diabetes mellitus (DM), dyslipidemia, chronic kidney disease (CKD), and cardiovascular disease (CVD), were self-reported. The outcome was all-cause mortality. RESULTS: Maintaining intermediate/ideal CVH attenuated the hazardous impact of hypertension (intermediate/ideal CVH: HR: 1.02; 95% CI: 0.71, 1.47; poor CVH: HR: 1.50; 95% CI: 1.16, 1.95), prediabetes (intermediate/ideal CVH: HR: 1.00; 95% CI: 0.64, 1.55; poor CVH: HR: 1.81; 95% CI: 1.30, 2.52), DM (intermediate/ideal CVH: HR: 2.53; 95% CI: 1.65, 3.87; poor CVH: HR: 5.02; 95% CI: 3.74, 6.76), dyslipidemia (intermediate/ideal CVH: HR: 1.13; 95% CI: 0.76, 1.68; poor CVH: HR: 1.29; 95% CI: 0.89, 1.86), and CKD (intermediate/ideal CVH: HR: 1.36; 95% CI: 1.01, 1.84; poor CVH: HR: 1.84; 95% CI: 1.21, 2.79) on longevity ( P for interaction < 0.05). No significant interaction between CVD and CVH was observed in the association with mortality. CVH status significantly interacted with the associations between cardiometabolic comorbidities and the risk of mortality when the number of comorbidities increased up to 3. CONCLUSIONS: CVH significantly attenuated the detrimental impacts of cardiometabolic comorbidities on longevity, highlighting the protective role of CVH even in individuals with preexisting cardiometabolic diseases.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2025) conducted a cohort in Cardiometabolic comorbidities and cardiovascular health (n=8,635). Intermediate or ideal cardiovascular health (Life's Essential 8 score ≥50) vs. Poor cardiovascular health (Life's Essential 8 score <50) was evaluated on All-cause mortality (HR 0.47, 95% CI 0.38, 0.57). Maintaining intermediate or ideal cardiovascular health was associated with a 53% lower risk of all-cause mortality (HR 0.47) compared to poor cardiovascular health and significantly attenuated the detrimental impacts of cardiometabolic comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: